Advertisement

Topics

Companies Related to "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer" [Most Relevant Company Matches] - Page: 4 RSS

09:32 EDT 20th March 2019 | BioPortfolio

Here are the most relevant search results for "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Trial Gemcitabine Carboplatin With Without PARP1 Inhibitor Patients" Companies 76–100 of 4,400+

Probably Relevant

Alexion Pharmaceuticals Inc.

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemo...


DHP pharma

DHP specialises in the preparation, packaging and distribution of Investigational Medicinal Products and Clinical Trial Supplies for study phases 1 through 4 and subsequent compassionate use.All work is carried out in accordance with the EU Clinical Trial Directive 2001/20 and Good Manufacturing Practice as set out by the MHRA. DHP offers a meticulous and comprehensive service from design through ...

Nuvelo

Nuvelo, Inc. is a publicly traded biopharmaceutical company dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes several acute cardiovascular and oncology programs. The cardiovascular portfolio includes three programs: alfimeprase, a direct acting thr...


Focus Bio-Inova, Inc.

Our project managers have many years of experience in handling the demanding requirements of specimens logistics, site support, and data management that make clinical trials a success. Focus project managers are often used by our clinical trial partners to help make their trial more efficient and cost effective. We also offer a unique Information Technology infrastructure that captures all aspects...

TransPerfect Life Sciences

TransPerfect’s Trial Interactive solution provides a collaborative web-based platform for study start-up and eTMF that enables sponsors, CROs, IRBs, central laboratories, and other vendors to maintain and update clinical trial documentation in a secure online environment. With fully searchable solutions including investigator portals, Trial Interactiv...

Next Generation Clinical Research Consulting, Inc

Next Generation is a specialized CRO providing services to the Biotech and Pharma industries in clinical trial management and training. Our Specialties: Collaborations with smaller or emerging biotech and pharma companiesComplex projects and trial designsNovel productsAs a purposely small, niche CRO, Next Generation brings together expertise, creativity and personal service to meet your distinct...

Clinical Assistance Programs

Clinical Assistance Programs (CAP) is a clinical trial management organization. CAP provides site and data quality management, investigator training, and specialized compliance services to life science companies engaged in clinical trials.CAP was created to address many of the problems inherent in the clinical trial process such as site variability, data accuracy, investigator compliance, and the ...

Kowa Company, Ltd.

Kowa Company, Ltd. (Headquarters: Nagoya, Japan , President & CEO: Yoshihiro Miwa, "Kowa") is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and commercial activities in the fields of pharmaceutical, life science, information technology, textiles, machinery and v...

Respicardia

Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to developing implantable therapies designed to improve the respiratory and cardiovascular health of patients. The company’s initial product, the remedē® System, is an implantable stimulation device that is designed to restore a more regular breathing pat...

CardioVascular BioTherapeutics, Inc.

CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has FDA-authorization for a Phase II trial to treat severe Coronary Heart Disease (CVBT-141H) and a Phase I trial to treat Peripheral Arterial Disease (CVBT-141C). A Phase III trial to treat der...

Retina Implant AG

Retina Implant, AG is the leading developer of subretinal implants for partially sighted and blind patients. After extensive research with German university hospitals which began in 1996, Retina Implant, AG was founded by Dr. Eberhart Zrenner and his colleagues in 2003 with the goal of developing the first fully-functioning electronic retinal prosthesis to...

Dezima Pharma

Dezima Pharma was founded in 2012 by Prof. John Kastelein, Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, The Netherlands, and seed-financed by Forbion Capital Partners and BioGeneration Ventures, to develop novel products to treat dyslipidemic patients suffering from cardiovascul...

Azaya Therapeutics Inc.

Azaya Therapeutics, Inc. is an oncology company focused on developing more effective cancer treatments through its novel nanotechnology platform. Azaya’s patented Protein Stabilized Liposomes™ (PSL) platform allows for high-dose delivery of potent cytotoxics with potentially lower side effects. ATI-1123, is a novel liposomal encapsulation of Doce...

Biotie Therapies

Biotie Therapies is a drug development biotechnology company with a focus on dependence disorders, inflammatory diseases and thrombosis.The most advanced drugs in development are nalmefene for alcoholism (phase III) and impulse control disorders (phase II), monoclonal VAP-1 antibody and small molecule VAP-1 SSAO enzyme inhibitor for inflammatory diseases (late preclinical), and recombinant biohepa...

ClinicalConnection, Inc.

ClinicalConnection.com (www.ClinicalConnection.com) has referred more than 150,000 patients to clinical trials and featured over 10,000 studies. Headquartered in Boston, Massachusetts, ClinicalConnection, Inc. provides a suite of patient recruitment services for the pharmaceutical development and medical device sectors. Services include customized clinical...

Arch Oncology, Inc.

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative...

Global Coalition for Adaptive Research

The Global Coalition for Adaptive Research (GCAR) is a 501(c)(3) non-profit charitable organization, comprised of some of the world’s foremost physicians, clinical researchers and investigators united in expediting the discovery and development of cures for patients with rare and deadly diseases. As its first priority, GCAR is sponsoring GBM AGILE, an...

OSI Pharmaceuticals

OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for patients with cancer, diabetes, and obesity. We specialize in the discovery and development of innovative molecular targeted therapies that address significant unmet medical needs, and st...

ArQule, Inc.

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 clinical development, is ARQ 197, an in...

Longboat Clinical

Longboat is a clinical trials software company dedicated to generating better study outcomes by creating a complete support structure for site staff, patients, monitors, and study teams - where protocol compliance becomes easy and instinctive. In the complex world of clinical development, Longboat’s cloud-based site and patient engagement platform emp...

Prosidion Ltd

(OSI) Prosidion is the diabetes and obesity business group within OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. (OSI) Prosidion's lead compound PSN9301 is a Dipeptidyl Peptidase IV (DP-IV) inhibitor currently in Phase II clinical trials. PSN357, a glycogen phosphorylase inhibitor, is undergoing Ph...

Trial Masters Ltd

Trial Masters Ltd., specializing in clinical trials since 1996, was one of the first CROs to be set up in the Central & Eastern European region. With a proven track record of managing avariety of clinical trials we are continually expanding our field of activity both geographically as well as by enlarging our portfolio of services.

Research Solutions, LLC

Research Solutions' mission is to provide quality and timely clinical data through efficient site selection and trial management services to assist the pharmaceutical and biotechnology industries in bringing new and important drug and product discoveries to patients in need.

Molecular Innovations Incorporated

Plasminogen Activator Inhibitor 1 (PAI-1)FibronectinPolyclonal AntibodiesMonoclonal AntibodiesImmobilized ProteinsELISA ASSAYSOther ReagentsVitronectinRelated Protein Reagents

Viventia Biotech Inc

Viventia Biotech Inc. is a biopharmaceutical company advancing a new generation of monoclonal antibody therapeutics designed to offer safer, more beneficial therapies for cancer patients. Viventia’s lead product candidate Proxinium™ continues on an aggressive clinical development schedule. Viventia has initiated a Phase II North American clinical trial and concurrently commenced a pivotal Phas...


More From BioPortfolio on "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks